M Kelly Nicholas

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. doi request reprint Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges
    M Kelly Nicholas
    Department of Neurology, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 38:243-53. 2011
  2. doi request reprint Glioblastoma multiforme: evidence-based approach to therapy
    M Kelly Nicholas
    University of Chicago, Department of Neurology, MC 2030, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Expert Rev Anticancer Ther 7:S23-7. 2007
  3. ncbi request reprint Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas
    M Kelly Nicholas
    Department of Neurology, University of Chicago, IL 60637, USA
    Clin Cancer Res 12:7261-70. 2006
  4. ncbi request reprint Chemotherapy for malignant glioma
    M Kelly Nicholas
    Department of Neurology, University of Chicago, 5801 South Ellis Ave, Chicago, IL 60637, USA
    Expert Rev Neurother 5:S41-9. 2005
  5. doi request reprint Emerging therapies for malignant glioma
    Rimas V Lukas
    University of Chicago, Department of Neurology, MC 2030, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Expert Rev Anticancer Ther 7:S29-36. 2007
  6. doi request reprint A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
    Jeffrey J Raizer
    Department of Neurology, Northwestern University, Chicago, IL, USA
    Cancer 116:5297-305. 2010
  7. pmc A phase I study of continuous infusion cilengitide in patients with solid tumors
    Peter H O'Donnell
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    Invest New Drugs 30:604-10. 2012
  8. pmc A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    University of California, San Francisco, San Francisco, California 94143 0372, USA
    Neuro Oncol 8:189-93. 2006
  9. ncbi request reprint Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival
    Ralph P Ermoian
    Department of Radiation Oncology, The University of California, San Francisco 94143, USA
    Clin Cancer Res 8:1100-6. 2002
  10. ncbi request reprint Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004

Collaborators

Detail Information

Publications17

  1. doi request reprint Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges
    M Kelly Nicholas
    Department of Neurology, University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 38:243-53. 2011
    ..In this review, we discuss recent attempts to exploit new molecular insights, consider the reasons for slow progress in developing better treatments, and examine future therapeutic options...
  2. doi request reprint Glioblastoma multiforme: evidence-based approach to therapy
    M Kelly Nicholas
    University of Chicago, Department of Neurology, MC 2030, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Expert Rev Anticancer Ther 7:S23-7. 2007
    ..This review will focus on the current standard of care in the USA for newly diagnosed GBM, focusing on the evidence supporting that care...
  3. ncbi request reprint Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas
    M Kelly Nicholas
    Department of Neurology, University of Chicago, IL 60637, USA
    Clin Cancer Res 12:7261-70. 2006
    ..We will also consider the ways in which specific EGFR alterations common to glioma reflect outcomes following treatment with targeted therapies, all with an eye towards applying this understanding to improved patient outcomes...
  4. ncbi request reprint Chemotherapy for malignant glioma
    M Kelly Nicholas
    Department of Neurology, University of Chicago, 5801 South Ellis Ave, Chicago, IL 60637, USA
    Expert Rev Neurother 5:S41-9. 2005
    ..This review will focus on medical therapies in the treatment of malignant glioma, never losing sight of their place as one of several therapeutic modalities used to confront brain cancer...
  5. doi request reprint Emerging therapies for malignant glioma
    Rimas V Lukas
    University of Chicago, Department of Neurology, MC 2030, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Expert Rev Anticancer Ther 7:S29-36. 2007
    ..Inhibitors of angiogenesis will also be discussed. Some 'targeted' therapies are less specific than others, working on more than one pathway or receptor, thus complex interactions are possible...
  6. doi request reprint A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
    Jeffrey J Raizer
    Department of Neurology, Northwestern University, Chicago, IL, USA
    Cancer 116:5297-305. 2010
    ..The authors evaluated a 3-week schedule of bevacizumab in patients with recurrent high-grade glioma (HGG)...
  7. pmc A phase I study of continuous infusion cilengitide in patients with solid tumors
    Peter H O'Donnell
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
    Invest New Drugs 30:604-10. 2012
    ..However, cilengitide has a short half-life of 3-5 h with no evidence of drug accumulation. These data prompted the initiation of this phase I study of continuous infusion cilengitide...
  8. pmc A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    University of California, San Francisco, San Francisco, California 94143 0372, USA
    Neuro Oncol 8:189-93. 2006
    ..52) for AG patients. Toxicity for the group included diarrhea and myelosuppression. We conclude that the recommended phase 2 dose of CPT-11 for patients with or without EIAED was ineffective on this schedule, in this patient population...
  9. ncbi request reprint Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival
    Ralph P Ermoian
    Department of Radiation Oncology, The University of California, San Francisco 94143, USA
    Clin Cancer Res 8:1100-6. 2002
    ..This study assessed whether putative effectors of phosphatidylinositol3-kinase, including PTEN, protein kinase B (PKB), and p27(kip1), correlate with each other, with glioma histology, and with patient outcome...
  10. ncbi request reprint Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004
    ..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas...
  11. ncbi request reprint Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 60:353-7. 2004
    ....
  12. pmc Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme
    David A Larson
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:119-26. 2004
    ..We conclude that permanent 125I brachytherapy for recurrent or progressive GM is well tolerated. Survival time was comparable to that of a similar group of patients treated with temporary brachytherapy...
  13. pmc Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:44-54. 2004
    ..A phase 2 study of patients with recurrent malignant glioma is ongoing to assess the efficacy of CPT-11 when the dose is stratified according to the use of EIAEDs...
  14. pmc Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:33-7. 2004
    ..We conclude that BCNU plus temozolomide when used in these doses and schedule has only modest activity, with significant toxicity, and appears to be no more effective than single-agent temozolomide...
  15. ncbi request reprint Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study
    Kurt A Jaeckle
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 21:2305-11. 2003
    ..This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG...
  16. ncbi request reprint Melanoma chemoprevention: a role for statins or fibrates?
    Robert P Dellavalle
    Department of Dermatology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Am J Ther 10:203-10. 2003
    ..This article reviews melanoma biology and the clinical evidence for the use of lipid-lowering medications for melanoma chemoprevention and/or adjuvant chemotherapy...
  17. pmc Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme
    Yu Liang
    Preuss Laboratory for Molecular Neuro oncology and Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 102:5814-9. 2005
    ..Our analyses thus identify and validate a prognostic marker of both biologic and clinical significance and provide a series of putative markers for additional evaluation...